Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Provectus Biopharmaceuticals, Inc. (PVCT : OTCBB)

• Company Description    Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $0.06 Daily Weekly Monthly 20 Day Moving Average: 215,251 shares Shares Outstanding: 419.45 (millions) Market Capitalization: $23.66 (millions) Beta: 0.14 52 Week High: $0.08 52 Week Low: $0.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.00% 5.88% 12 Week -17.42% -9.21% Year To Date 2.55% 25.30%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10025 INVESTMENT DRIVE SUITE 250 - KNOXVILLE,TN 37932 USA ph: 866-594-5999 fax: 866-998-0005 investorrelations@pvct.com http://www.provectusbio.com

• General Corporate Information    Officers Heather Raines - Chief Financial Officer Ed Pershing - Chairman of the Board Dominic Rodrigues - Vice Chairman of the Board Bruce Horowitz - Chief Operating Officer Webster Bailey - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74373P108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/21 Next Expected EPS Date: 05/24/22 Share - Related Items Shares Outstanding: 419.45 Most Recent Split Date: (:1) Beta: 0.14 Market Capitalization: $23.66 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/24/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -267.27 12/31/21 - -414.21 09/30/21 - -984.67 Current Ratio 03/31/22 - 0.35 12/31/21 - 0.45 09/30/21 - 0.14 Quick Ratio 03/31/22 - 0.35 12/31/21 - 0.45 09/30/21 - 0.14 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -2,612.40 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - -0.01 12/31/21 - -0.01 09/30/21 - -0.01 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©